Apremilast-话题@MedSci

#Apremilast#

6篇内容 | 1264人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2118572, encodeId=053a21185e2c9, content=<a href='/topic/show?id=2120e16682b' target=_blank style='color:#2F92EE;'>#白塞氏病#</a>(BD)是一种由细胞毒性T细胞和中性粒细胞介导的全身性血管炎。<a href='/topic/show?id=14109e840d4' target=_blank style='color:#2F92EE;'>#阿普斯特#</a>(<a href='/topic/show?id=46bc26903b' target=_blank style='color:#2F92EE;'>#Apremilast#</a>)是一种选择性抑制<a href='/topic/show?id=0092e38496e' target=_blank style='color:#2F92EE;'>#磷酸二酯酶4#</a>(PDE4)的口服小分子药物，最近已被批准用于治疗BD, objectTitle=A&R：磷酸二酯酶4(PDE4)阻断降低白塞病中性粒细胞的激活, objectType=article, longId=762155, objectId=33b8e62155d5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230309/1678295523215_5610093.png, objectUrl=/article/show_article.do?id=33b8e62155d5, replyNumber=0, likeNumber=162, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=33b8e62155d5, moduleTitle=A&R：磷酸二酯酶4(PDE4)阻断降低白塞病中性粒细胞的激活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33b8e62155d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027886, encodeId=614d202e886bf, content=<a href='/topic/show?id=46bc26903b' target=_blank style='color:#2F92EE;'>#Apremilast#</a>, objectTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, objectType=article, longId=301742, objectId=ea63301e42f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea63301e42f2, replyNumber=0, likeNumber=91, createdTime=2022-06-25, rootId=0, userName=lqrandywkz, userId=86b7385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea63301e42f2, moduleTitle=Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea63301e42f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027885, encodeId=4b6c202e8850d, content=<a href='/topic/show?id=46bc26903b' target=_blank style='color:#2F92EE;'>#Apremilast#</a>, objectTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, objectType=article, longId=202961, objectId=601d202961a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601d202961a3, replyNumber=0, likeNumber=129, createdTime=2021-05-17, rootId=0, userName=lqrandywkz, userId=86b7385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601d202961a3, moduleTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=601d202961a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027884, encodeId=9cef202e88442, content=<a href='/topic/show?id=46bc26903b' target=_blank style='color:#2F92EE;'>#Apremilast#</a>, objectTitle=Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果, objectType=article, longId=193626, objectId=9c621936262c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c621936262c, replyNumber=0, likeNumber=125, createdTime=2020-07-30, rootId=0, userName=lqrandywkz, userId=86b7385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c621936262c, moduleTitle=Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c621936262c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027883, encodeId=2da1202e883fa, content=<a href='/topic/show?id=46bc26903b' target=_blank style='color:#2F92EE;'>#Apremilast#</a>, objectTitle=NEJM：Apremilast治疗白塞病相关口腔溃疡, objectType=article, longId=183026, objectId=409018302667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=409018302667, replyNumber=0, likeNumber=148, createdTime=2020-07-06, rootId=0, userName=lqrandywkz, userId=86b7385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=409018302667, moduleTitle=NEJM：Apremilast治疗白塞病相关口腔溃疡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=409018302667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2027882, encodeId=4558202e88276, content=<a href='/topic/show?id=46bc26903b' target=_blank style='color:#2F92EE;'>#Apremilast#</a>, objectTitle=Celgene新药apremilast临床三期研究失败, objectType=article, longId=37785, objectId=499c3e78532, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=499c3e78532, replyNumber=0, likeNumber=139, createdTime=2015-04-30, rootId=0, userName=lqrandywkz, userId=86b7385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=499c3e78532, moduleTitle=Celgene新药apremilast临床三期研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=499c3e78532)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Apremilast

2020-05-29

showtest (审核中...)

前往app查看评论内容

#白塞氏病#(BD)是一种由细胞毒性T细胞和中性粒细胞介导的全身性血管炎。#阿普斯特#(#Apremilast#)是一种选择性抑制#磷酸二酯酶4#(PDE4)的口服小分子药物，最近已被批准用于治疗BD

A&R：磷酸二酯酶4(PDE4)阻断降低白塞病中性粒细胞的激活

2023-03-10发表于上海

lqrandywkz (审核中...)

前往app查看评论内容

#Apremilast#

Rheumatology：Apremilast单药治疗DMARD无效的活动性银屑病关节炎的长期疗效

2022-06-25

lqrandywkz (审核中...)

前往app查看评论内容

#Apremilast#

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

2021-05-17

lqrandywkz (审核中...)

前往app查看评论内容

#Apremilast#

Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果

2020-07-30

lqrandywkz (审核中...)

前往app查看评论内容

#Apremilast#

NEJM：Apremilast治疗白塞病相关口腔溃疡

2020-07-06

lqrandywkz (审核中...)

前往app查看评论内容

#Apremilast#

Celgene新药apremilast临床三期研究失败

2015-04-30

科室
- - 订阅+
  - 更多科室
工具
服务